CJC-1295 with DAC vs Proviron
Well Studied vs Well Studied
synergistic Mechanism-based · 60% Proviron helps manage estrogen conversion from CJC-1295 with DAC. This is a common and recommended combination. Adjust AI dose based on bloodwork — avoid crashing estrogen.
Molecular Data
CJC-1295 with DAC Proviron
Weight 3,647.28 Da 304.47 Da
Half-life 6-8 days ~12 hours
Chain 30 amino acids —
Type GHRH analog with DAC DHT derivative (C20H32O2)
Key Benefits
CJC-1295 with DAC
01 Convenient weekly dosing
02 Sustained GH/IGF-1 elevation
03 6-8 day half-life
04 Significant body composition changes
Proviron
01 Strong SHBG binding frees more circulating testosterone, enhancing TRT efficacy
02 Improved mood, motivation, confidence, and overall sense of well-being
03 Significant enhancement of libido and sexual function
04 Anti-estrogenic effect reduces the need for dedicated aromatase inhibitors
05 Harder, drier, more defined physical appearance without water retention
06 Minimal hepatotoxicity due to absence of 17-alpha alkylation
07 May improve sperm quality at low doses in subfertile men
08 Rapid onset of subjective well-being effects (often within days)
Dosing Protocols
CJC-1295 with DAC
1-2mg weekly / Once or twice weekly (e.g., Monday/Thursday for split dosing)
Conservative Anti-Aging 1mg Once weekly
Standard Protocol 2mg Once weekly
Split Dosing 1mg Twice weekly (Mon/Thu)
Loading Protocol 2mg first week, then 1mg Weekly
Proviron
25-75 mg/day / 1-3x per day (oral)
Side Effects
CJC-1295 with DAC
Water retention
Joint pain
Carpal tunnel symptoms
Proviron
Accelerated hair thinning or loss in those predisposed to male pattern baldness (DHT-mediated)
Mild suppression of endogenous testosterone at higher doses (though less suppressive than most AAS)
Oily skin and increased sebum production
Mild HDL cholesterol suppression with extended use
Increased body hair growth
Contraindications
Diabetes history
Cancer history
Predisposed sleep apnea
Prostate cancer (active or history of androgen-sensitive prostate cancer)
Severe liver impairment (though hepatotoxicity risk is minimal)
Breast cancer in males
Hypersensitivity to mesterolone or any excipients
Women who are pregnant or may become pregnant (androgenic effects on fetus)
Research Evidence
CJC-1295 with DAC Proviron
Status Well Studied Well Studied
References 4 studies 5 studies
Latest 2025 —
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.